about
Cysteinyl Leukotrienes Pathway Genes, Atopic Asthma and Drug Response: From Population Isolates to Large Genome-Wide Association StudiesGenome-wide association analysis in asthma subjects identifies SPATS2L as a novel bronchodilator response genePharmacogenetics of chronic obstructive pulmonary disease: challenges and opportunities.Genetic polymorphisms and associated susceptibility to asthma.Beta 1- and beta 2-adrenoceptor polymorphisms and cardiovascular diseases.Beta-2-Adrenergic Receptor Methylation Influences Asthma Phenotype in The School Inner City Asthma Study.Very important pharmacogene summary ADRB2.Biochemical basis of asthma therapy.Clinical asthma phenotyping: A trial for bridging gaps in asthma managementβ2-Adrenergic receptor promoter haplotype influences the severity of acute viral respiratory tract infection during infancy: a prospective cohort study.A genome-wide analysis of the response to inhaled β2-agonists in chronic obstructive pulmonary disease.What have we learned from prospective cohort studies of asthma in children?Genetic association analysis of COPD candidate genes with bronchodilator responsiveness.Genetics of chronic obstructive pulmonary disease: a succinct review, future avenues and prospective clinical applications.Asthma: Gln27Glu and Arg16Gly polymorphisms of the beta2-adrenergic receptor gene as risk factors.β-2 adrenergic receptor gene methylation is associated with decreased asthma severity in inner-city schoolchildren: asthma and rhinitis.Pharmacogenetics and human genetic polymorphisms.SNPs in genes encoding G proteins in pharmacogenetics.Association between ß2-adrenergic receptor gene polymorphisms and adverse events of ritodrine in the treatment of preterm labor: a prospective observational study.
P2860
Q28067073-F6F955E3-0CA3-425E-A124-513C4751A3F7Q28481005-79EB7F04-442C-4A85-9ECD-59656E285DD0Q33706037-6DC5BB1C-5989-46DC-A06C-44BD6D8FB79EQ34342451-B2C4DA78-F19D-483E-8A9B-7D1F6E64AC8EQ34658477-5429E2E9-34B4-4BA6-BFBE-5195A7B2D08BQ34906177-FE2722B9-D24D-45BB-89FA-DD2A9B73C69BQ34994884-A059EF73-C748-44C7-BFB7-5285DCCD0D34Q35312155-B1B36C44-BD7B-4D02-9920-8FE43914F02BQ35626634-E984621C-B074-4E13-A8AB-7F12F419CFA5Q35775111-D7D79054-2301-498C-B9EA-4CD5F4F2A159Q36844920-E682101E-19AB-4C1D-A71A-65E9D25202B7Q37333398-E2101565-9283-48F2-918D-51D4CDAB2FDAQ37351330-9737442E-988E-4E01-A0FA-34F2100D83E8Q37448915-763B8250-B0C8-44D5-B175-D8C98392EB06Q37595504-3159EA05-85BC-4869-907B-DE680ADE5101Q37706994-3AE68DF8-E087-4E35-B752-10CA4DE42CDCQ37772183-3912569C-DA78-460F-A44A-1EDA915BE1FCQ37880876-CD2FF114-2877-4ED8-A036-597C49B7FF39Q46977246-89B78A3D-DB90-44F7-8E9F-01E77E76E709
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Clinical consequences of ADRbeta2 polymorphisms.
@en
Clinical consequences of ADRbeta2 polymorphisms.
@nl
type
label
Clinical consequences of ADRbeta2 polymorphisms.
@en
Clinical consequences of ADRbeta2 polymorphisms.
@nl
prefLabel
Clinical consequences of ADRbeta2 polymorphisms.
@en
Clinical consequences of ADRbeta2 polymorphisms.
@nl
P2860
P356
P1433
P1476
Clinical consequences of ADRbeta2 polymorphisms.
@en
P2093
Gregory A Hawkins
Scott T Weiss
P2860
P304
P356
10.2217/14622416.9.3.349
P577
2008-03-01T00:00:00Z